Augustinus Bader is valued at a billion dollars on revenue of about two hundred million — five to one. That's exactly what was paid for a brand built by a celebrity and on celebrity. Yet the brand itself sells science. This audit shows that investors value it not by the asset it calls its own.
Six findings with a confidence rating: high — several independent sources, medium — one, estimate — the author's calculation.
A billion on two hundred million of revenue is 5.0× revenue. Rhode sold for $1.0bn on $212m — 4.7×. Aesop for $2.53bn on $537m — also 4.7×. The average beauty multiple is 3.6×; the ordinary-premium band is 3–5×, the celebrity-and-scarce band 5–8×.
111Skin publicly names Victoria Beckham and Jennifer Aniston as its advocates — the same people Augustinus Bader cites. The asset that drives sales doesn't belong to the brand and isn't exclusive.
Cosmetics aren't required to publish clinical trials, the founder's scientific biography is real and published, and the brand does have studies. The precise complaint is narrower: they are sponsored by the brand itself, and there is no independent validation of the formula's superiority.
The $25m round that set the billion-dollar valuation included Antoine Arnault, Natalia Vodianova and the chairman of Diageo's board. Impala and General Atlantic led it. This changes the nature of the risk: the question isn't whether the big players will come, but on what terms the exit happens.
The flagship cream costs about $6.2 per millilitre, when the top of the premium segment is described as "above two dollars." A premium of that size needs a justification a sponsored study can't provide.
Dr. Barbara Sturm, with revenue of about €70m, was bought by Puig; the founder kept a minority stake and became chief product officer and brand ambassador. The buyer pays for the founder's continued presence — meaning key-person risk isn't removed by the deal but priced into it.
Before judging the brand, you need to understand exactly which market it plays in and how much that market helps it.
The market helps, but moderately. Luxury skincare grows 7.5% a year. The brand's target is plus 50% over the period — from two hundred million to three hundred by 2026. That's six to seven times faster than the category, meaning all of the growth has to be won from competitors or created in new geographies.
The stated expansion directions are China, Asia-Pacific and travel retail. The choice is logical: category growth is higher there and competitor density is lower. But those are also the most expensive markets to enter and the most sensitive to regulatory differences in efficacy claims.
The industry describes the brand's place directly. It is placed in the "skinstitutional" cohort — alongside SkinCeuticals and La Mer, which set the ceiling price per unit of product. The company is flattering and dangerous at once: the same cohort contains SkinCeuticals, which occupies the top tier of the evidence hierarchy — the very one Augustinus Bader claims.
There are no public accounts, so the trajectory is assembled from scattered press reports. Every point is dated.
Three points give a sense of the pace: a target of over $130m for 2024 at a stated growth rate of about 40%, then an estimate of about $200m, and a target of $300m by 2026. Each segment implies growth of about half over the period.
What this means for the valuation. At $200m of revenue, the billion-dollar valuation gives a 5.0× multiple. Hitting the $300m target puts that same billion at 3.3× — meaning meeting plan by itself moves the company from a stretched valuation to a comfortable one. The reverse is also true: missing the target leaves the company with a celebrity-brand multiple and no celebrity growth rate.
Direct-to-consumer sales via the website account for 60% of revenue and grew 35% year on year; premium retail is about 30%. The structure is healthy: margin and shop window at the same time.
Price per millilitre is the only way to compare products of different sizes. The spread within the category exceeds thirtyfold.
The flagship cream costs $185 for 30 millilitres — about $6.2 per millilitre. Industry reviews describe the top of the premium segment as "above two dollars per millilitre," and the bottom as about six cents for large-volume drugstore products.
The brand costs roughly three times the top of the segment it's placed in. That's not a rebuke: a price premium is a legitimate strategy, and in luxury it is often justified by ritual, packaging and status. But a premium of that size needs a basis, and the brand chose science as its basis.
This is where the vulnerability described in section 05 arises. A premium justified by status can't be checked and is therefore invulnerable. A premium justified by the superiority of the formula can be checked — and defending it requires evidence, of which the brand has less than its cohort neighbour.
The common complaint is "the brand has no clinical evidence." In its original form it doesn't survive scrutiny, and an audit built on it would collapse at the first objection.
The precise statement of the problem is different. The studies on the proprietary complex are sponsored by the brand itself, and there is no independent, peer-reviewed validation of superiority over a well-formulated moisturiser in the public domain. This doesn't breach the legal bar.
The vulnerability is elsewhere: the brand has voluntarily set itself a bar higher than the legal one. The regulator judges by proportionality, but anyone who sells science will be judged by a scientific standard — by independent peer review. That is a court the brand walked into itself, and in it, it loses to its price-cohort neighbour.
Not an assessment of product quality, but an assessment of how defensible the position is.
| Tier | Who occupies it | What backs it |
|---|---|---|
| Independent peer review | SkinCeuticals | The flagship serum is cited in more than 100 clinical studies; the brand was founded by a Duke University professor |
| Sponsored studies | Augustinus Bader | Clinical and consumer trials paid for by the brand; no independent validation of formula superiority |
| Scientific narrative | La Mer, 111Skin, Noble Panacea | A development story and a proprietary ingredient, with no public evidence base on the finished formula |
The brand sits in the middle — above the bulk of luxury and below the single player on the top tier. The problem is that the top tier belongs to L'Oréal: SkinCeuticals is in its portfolio alongside CeraVe and La Roche-Posay, and together the three account for about 14% of category mentions.
So on the evidence axis the brand competes not with equals but with a company whose research budget is not comparable by order of magnitude.
Augustinus Bader relies on unpaid mentions from Victoria Beckham, Gwyneth Paltrow and Jennifer Aniston; the new wave is Margot Robbie, Hailey Bieber, Dua Lipa.
111Skin, in its own materials, names Lady Gaga, Jennifer Aniston, Cate Blanchett and Victoria Beckham as its advocates. Two of the four names match word for word.
This moves the question from guesswork to fact: the celebrity halo in this category is not a moat but shared infrastructure. It is leased by everyone at once and gives exclusivity to no one.
There is a sharper illustration. Hailey Bieber is among the new wave of the brand's endorsers — and is also the founder of Rhode, sold for a billion dollars on $212m of revenue. A celebrity's own brand was valued at practically the same multiple as the science brand she endorses. The market doesn't price these two assets differently.
A reverse calculation from the price. If the brand is worth a billion, which assumptions have to hold for that to be fair.
A 5.0× revenue multiple puts the brand above the industry average, above both comparable deals, and on the boundary between the ordinary-premium band and the band of celebrity and strategically scarce assets.
For that price to be fair, one of three things has to hold.
First: growth. Hitting the $300m target brings the multiple to 3.3× — into the middle of the premium band. This is the most likely justification scenario, and also the most checkable: the deadline falls this year.
Second: margin. Deals in the category closed at EBITDA margins from 20 to 50%. If a brand with 60% direct-to-consumer revenue holds the top of that range, the profit multiple is moderate even at a high revenue multiple. There is no public margin data — this is the key uncheckable parameter of the whole valuation.
Third: scarcity. A strategically rare asset is worth more than the calculation. A professor-founder with a real scientific biography is exactly such an asset, and it can't be reproduced. But scarcity in the price means the founder is what's being bought — not the formula and not the brand name.
What was bought in the category, and at what price. All deals are public; the sums are stated in open sources.
| Deal | Price and revenue | Multiple | The lesson |
|---|---|---|---|
| Rhode → e.l.f. Beauty, 2025 | $1.0bn / $212m | 4.7× | A celebrity brand of the same size valued almost the same as a science one |
| Aesop → L'Oréal, 2023 | $2.53bn / $537m | 4.7× | The same multiple at twice the scale: size alone gives no premium |
| Dr. Barbara Sturm → Puig | undisclosed / ≈€70m | — | The founder kept a stake and became brand ambassador. A ready succession template |
| Medik8 → L'Oréal | undisclosed | ≈20× EBITDA | An evidence-backed science brand is paid for on profit, not revenue |
| Paula's Choice → Unilever | undisclosed | ≈18× EBITDA | The same order for a brand with a strong evidence reputation |
| Augustinus Bader, 2022 valuation | $1.0bn / ≈$200m | 5.0× | Above both comparable deals on revenue |
An observation worth separate attention. The two deals where a profit multiple is disclosed — Medik8 and Paula's Choice — are brands with a scientific or evidence reputation, and both were bought by large holding companies at 18–20× EBITDA. The two deals where a revenue multiple is disclosed — Rhode and Aesop, brands with cultural and aesthetic strength — are both at 4.7×.
On this data, the category pays for science through profit and for cultural capital through revenue. Augustinus Bader is valued on the second principle, though it positions on the first.
A section usually absent from marketing audits, but without which you can't tell where the brand is heading.
| Buyer | Motive | What's in the way |
|---|---|---|
| L'Oréal | Close the top price tier next to SkinCeuticals and enter skin longevity with a ready name | Already owns the top tier of the evidence hierarchy. Why pay for a weaker position on the same axis |
| LVMH | Luxury skincare with a scientific legend and a founder-persona — exactly their format | Formally free, but capital from this circle is already in the company as a private investment |
| Estée Lauder | A direct replacement for an ageing franchise in the top price segment | Its own difficulties in premium skincare; appetite for large acquisitions is limited |
| Puig | Has already assembled a science-and-persona brand in this category and knows how to integrate one | The acquisition is an order of magnitude larger than the previous one |
| Continuing as an independent company | The founder keeps control; investors get liquidity through secondary sales | Requires delivering the growth plan without a holding company's resources in new markets |
The investor makeup has to be stated carefully. The $25m round that set the billion-dollar valuation included Antoine Arnault, Natalia Vodianova, the chairman of Diageo's board and the photographer Mert Alas; Impala and General Atlantic led it. These are private investments by specific individuals, not corporate investments by the holding companies they represent. Conflating the two would be a mistake.
But the strategic conclusion changes anyway. The previous version of the audit framed the risk as "conglomerates are entering the category." It's more accurate to say: capital from this circle is already inside, and the question isn't the arrival of competitors but the terms and timing of an exit. Which means the priority shifts from defence to preparing the asset for valuation.
The likelihood and impact ratings are the author's; the grounds are stated. Order is by one multiplied by the other.
The target implies about 50% growth against category growth of 7.5% a year. All of the gain has to be won from competitors or created in China and travel retail — the most expensive and regulatorily complex markets.
The whole construction rests on the founder's name and biography. It is the one asset that can't be reproduced — and also the one point whose failure devalues everything else.
While publication isn't mandatory, sponsored trials are enough. But a player with a hundred citations already sets the reference, and if independent peer review becomes a market expectation, the bar moves to whoever has cleared it.
The halo is shared with a competitor word for word and migrates freely. A generational change of faces is already underway: from Paltrow and Aniston to Bieber and Dua Lipa.
60% of revenue goes through the brand's own site: excellent margin and full customer data, but also full dependence on the cost of traffic and on platform policies toward efficacy claims.
When Puig bought Dr. Barbara Sturm, the founder kept a minority stake and took the role of chief product officer and brand ambassador. That is not a courtesy but a condition of the deal: the buyer was acquiring not a formula but a person's continued presence.
For Augustinus Bader the conclusion is twofold. On one hand, the template works and the path is known. On the other — it means key-person risk isn't removed by the deal but transferred to the buyer, and the buyer understands this and prices it in.
From this comes a practical task that marketing audits don't usually set: convert part of the founder's authority into an institutional form while he is present. A scientific board with external names, publications with co-authors, a named methodology that is separable from the surname. Each such step reduces the key-person discount under any exit scenario.
The positioning is built on science. But the capital market gave the brand a revenue multiple — 5.0 — that is, exactly the metric used to value cultural and celebrity assets. Science brands in the same category are paid for on profit: Medik8 at about 20× EBITDA, Paula's Choice at about 18×.
At the same time the celebrity asset that actually drives sales is shared with a direct competitor word for word — two of the names on 111Skin's list match.
The result is a construction in which the stated moat structurally loses to a conglomerate, the working moat isn't exclusive, and the one genuinely defensible asset — the founder figure — is the quietest thing in the positioning.
The fork is decided within this year: the deadline on the $300m target falls now.
Revenue reaches $300m, the multiple comes to 3.3× — the comfortable middle of the premium band. Expansion into Asia and travel retail confirmed by the numbers.
The brand stops defending the superiority of the formula and moves the weight onto the irreproducible figure. The price premium is justified by authorship, not by evidence.
Growth lags, the multiple stays high with nothing to back it, and the evidence bar in the category shifts up. The premium stops reading as justified.
Five decisions in priority order. All are about moving the weight from the axis where the brand loses to the axis where it is invulnerable.
Science is the axis where the larger research budget wins, and it belongs to L'Oréal. The founder is the axis where a competitor can do nothing. "Developed by a professor who spent thirty years on tissue regeneration" is better defended than "our formula is more effective": the first is checkable and irreproducible, the second demands an endless evidence race.
An external scientific board, publications with co-authors, a named methodology separable from the surname. This is direct work on value: the Puig template shows the buyer pays for the person's presence, so the key-person discount is counted in every deal. Each step of institutionalisation reduces that discount.
Not for marketing, but to remove the one justified complaint. By order of magnitude this is a fraction of a percent of annual revenue — a sum out of reach for a small competitor. Publish it in full, including the inconvenient results: half the value is in the openness itself.
Right now celebrities work as a "this is fashionable" signal — and the brand shares that signal with a competitor. Long-running usage stories over a span of years, instead of one-off mentions, create what can't be copied: accumulated time. The departure of one face then doesn't zero out the asset.
Not by cutting direct sales, but by faster growth of the professional channel — aesthetic medicine clinics. There the longevity category grows fastest, the audience is primed, the scientific argument meets an interlocutor able to judge it, and dependence on ad-platform policies falls.
The section without which an audit stays an opinion. The four strongest objections and honest answers.
"You sell science to buyers, not to scientists." A strong objection: for the end audience, the word "professor" and the word "study" work the same regardless of who funded the study. Answer: they work until the first prominent review, and the risk here isn't gradual erosion but a single event — the more expensive the higher the price premium.
"Sponsored studies are the industry norm." True, which is why the charge in its original form is cleared in section 05. But a norm protects whoever invokes it. A brand whose positioning is built on the superiority of its science can't shelter behind an industry norm — it has declared that it isn't like the others.
"A 5.0× multiple isn't inflated if the margin is high." The strongest of the four objections, and it's partly fair. Deals in the category closed at 20–50% margins, and a brand with 60% direct-to-consumer revenue can well hold the top of the range. There is no public margin data, so I frame the conclusion about the revenue multiple as an observation about a mismatch between metric and positioning, not as a claim of overvaluation.
"The name overlap at 111Skin proves nothing." Partly fair: a celebrity can use several products, and a brand mention doesn't imply a contract. But that is precisely the argument: if an asset can be mentioned without exclusive rights, it isn't a moat for anyone.
There is no profitability figure. The key parameter of the whole valuation is unavailable. Without it, a profit multiple can't be calculated, and a revenue multiple can only be interpreted against comparable deals.
Revenue is an estimate. The figure of about $200m is an estimate from the industry press, not accounts. The company doesn't publish officially.
The billion-dollar valuation is dated 2022. There have been secondary sales of stakes since, but no new public valuation. The current value could differ in either direction.
The terms of the Medik8, Paula's Choice and Dr. Barbara Sturm deals aren't fully disclosed. The profit multiples are known from industry reviews; the sums aren't.
There is no market-share figure for the brand in the category. On a $28bn luxury-skincare market, $200m of revenue is about 0.7%, but the sources' segment definitions don't match, so the comparison is approximate.
The investor makeup is known; the ownership structure isn't. The split of stakes between the founders, Impala, General Atlantic and the private investors isn't disclosed in open sources.
| Metric | Value | Source and status |
|---|---|---|
| The brand | ||
| Company valuation | $1.0bn | Press, 2022 round |
| Raised in the round | $25m | Press, fact |
| Revenue, estimate | ≈$200m | Press, estimate |
| Revenue target | $300m by 2026 | Press, company target |
| Previously stated target | >$130m for 2024 | Press, company target |
| Stated sales growth | up to 40% | Press |
| Direct-sales share | 60% | Press, Q1 2025 |
| Direct-channel growth | 35% year on year | Press |
| Premium retail share | ≈30% | Press |
| Flagship cream price | $185 / 30ml | Public price |
| Price per millilitre | ≈$6.2 | Author's calculation |
| Revenue multiple | ≈5.0× | Author's calculation |
| Comparable deals | ||
| Rhode → e.l.f. Beauty | $1.0bn / $212m | Press, 4.7× |
| Aesop → L'Oréal | $2.53bn / $537m | Press, 4.7× |
| Medik8 → L'Oréal | ≈20× EBITDA | Industry review |
| Paula's Choice → Unilever | ≈18× EBITDA | Industry review |
| Dr. Barbara Sturm → Puig | revenue ≈€70m | Press, sum undisclosed |
| Average beauty multiple | 3.6× revenue | Industry review, July 2025 |
| Ordinary-premium band | 3–5× | Same |
| Celebrity-and-scarce band | 5–8× | Same |
| Average EBITDA multiple | 14.9× | Same, against 9.8× in the consumer sector |
| Deal targets' profitability | 20–50% EBITDA | Same |
| The category | ||
| Luxury skincare, 2026 | $28.0bn | Report |
| Growth to 2030 | 7.5% | Report, forecast |
| Premium cosmetics, 2025 | $82.4bn | Report |
| US premium, H1 2026 | $17.1bn, +7% | Circana |
| US premium skincare growth | +9% | Circana |
| Price per ml, drugstore products | ≈$0.06 | Industry review |
| Price per ml, top of premium | >$2.00 | Same |